Based on the Curis Inc stock forecast from 1 analysts, the average analyst target price for Curis Inc is USD 18.67 over the next 12 months. Curis Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Curis Inc is Bearish, which is based on 2 positive signals and 6 negative signals. At the last closing, Curis Inc’s stock price was USD 1.29. Curis Inc’s stock price has changed by +11.21% over the past week, -54.58% over the past month and -91.56% over the last year.
No recent analyst target price found for Curis Inc
No recent average analyst rating found for Curis Inc
Company Overview Curis Inc
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts. Read Less
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/...Read More
Frequently Asked Questions About Curis Inc (CRIS) Stock
Based on ratings from 1 analysts Curis Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 3 buy, sell and hold ratings.
Unfortunately we do not have enough data on CRIS's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for CRIS is USD 18.67 over the next 12 months. The maximum analyst target price is USD 20 while the minimum anlayst target price is USD 16.
Unfortunately we do not have enough data on CRIS's stock to indicate if its overvalued.
The last closing price of CRIS's stock was USD 1.29.
The most recent market capitalization for CRIS is USD 0.02B.
Based on targets from 1 analysts, the average taret price for CRIS is projected at USD 18.67 over the next 12 months.
This means that CRIS's stock price may go up by +1,347.03% over the next 12 months.
We can't find any ETFs which contains Curis Inc's stock.
As per our most recent records Curis Inc has 49 Employees.
Curis Inc's registered address is Building C, Lexington, MA, United States, 02421.
You can get more information about it from Curis Inc's website at https://www.curis.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Curis Inc (CRIS) Stock
Based on ratings from 1 analysts Curis Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 3 buy, sell and hold ratings.
Unfortunately we do not have enough data on CRIS's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for CRIS is USD 18.67 over the next 12 months. The maximum analyst target price is USD 20 while the minimum anlayst target price is USD 16.
Unfortunately we do not have enough data on CRIS's stock to indicate if its overvalued.
The last closing price of CRIS's stock was USD 1.29.
The most recent market capitalization for CRIS is USD 0.02B.
Based on targets from 1 analysts, the average taret price for CRIS is projected at USD 18.67 over the next 12 months.
This means that CRIS's stock price may go up by +1,347.03% over the next 12 months.
We can't find any ETFs which contains Curis Inc's stock.
As per our most recent records Curis Inc has 49 Employees.
Curis Inc's registered address is Building C, Lexington, MA, United States, 02421.
You can get more information about it from Curis Inc's website at https://www.curis.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for CRIS !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
